河北医学
河北醫學
하북의학
HEBEI MEDICINE
2014年
4期
617-620
,共4页
炎症性肠病%美沙拉嗪%益生菌
炎癥性腸病%美沙拉嗪%益生菌
염증성장병%미사랍진%익생균
Inflammatory bowel disease%Mesalazine%Probiotics
目的：探讨美沙拉嗪联合益生菌治疗炎症性肠病的疗效。方法：采用回顾性分析方法，随机选取我院2010年3月至2012年9月收治的42例采用美沙拉嗪治疗和42例采用美沙拉嗪联合益生菌方法治疗的炎症性肠病患者的临床资料进行分析，根据治疗方法的不同分为联合组和对照组，比较两组在治疗8周时间后的内镜复查效果、最终临床疗效和不良反应情况。结果：治疗8周后内镜复查联合组总有效率为90．48％，对照组为80．95％；临床治疗效果联合组总有效率92．86％，对照组为30．95％；不良反应联合组发生5例，对照组发生23例；两组内镜复查效果、临床效果和不良反应发生情况对比差异均无统计学意义（ P＞0．05）。结论：美沙拉嗪联合益生菌治疗炎症性肠病具有很好的效果，值得临床推广应用。treatment and compared the two groups after 8 weeks of treatment effect of endoscopy review ， the final clini-cal efficacy and adverse reactions ．Result：After 8 weeks ， the total effective rate of combination group and was 90．48％and 80．95％and respectively；The total effective rate of clinical outcomes in combination group and the control group was 92．86％and 30．95％；Adverse reactions occurred five cases of the combined group and 23 cases in control group；groups endoscopic review effects ， clinical efficacy and adverse events were not significantly different compared between two groups ．Conclusion： Mesalazine combined probiotics for the treatment of inflammatory bowel disease has a good effect ， worthy of clinical application ．
目的：探討美沙拉嗪聯閤益生菌治療炎癥性腸病的療效。方法：採用迴顧性分析方法，隨機選取我院2010年3月至2012年9月收治的42例採用美沙拉嗪治療和42例採用美沙拉嗪聯閤益生菌方法治療的炎癥性腸病患者的臨床資料進行分析，根據治療方法的不同分為聯閤組和對照組，比較兩組在治療8週時間後的內鏡複查效果、最終臨床療效和不良反應情況。結果：治療8週後內鏡複查聯閤組總有效率為90．48％，對照組為80．95％；臨床治療效果聯閤組總有效率92．86％，對照組為30．95％；不良反應聯閤組髮生5例，對照組髮生23例；兩組內鏡複查效果、臨床效果和不良反應髮生情況對比差異均無統計學意義（ P＞0．05）。結論：美沙拉嗪聯閤益生菌治療炎癥性腸病具有很好的效果，值得臨床推廣應用。treatment and compared the two groups after 8 weeks of treatment effect of endoscopy review ， the final clini-cal efficacy and adverse reactions ．Result：After 8 weeks ， the total effective rate of combination group and was 90．48％and 80．95％and respectively；The total effective rate of clinical outcomes in combination group and the control group was 92．86％and 30．95％；Adverse reactions occurred five cases of the combined group and 23 cases in control group；groups endoscopic review effects ， clinical efficacy and adverse events were not significantly different compared between two groups ．Conclusion： Mesalazine combined probiotics for the treatment of inflammatory bowel disease has a good effect ， worthy of clinical application ．
목적：탐토미사랍진연합익생균치료염증성장병적료효。방법：채용회고성분석방법，수궤선취아원2010년3월지2012년9월수치적42례채용미사랍진치료화42례채용미사랍진연합익생균방법치료적염증성장병환자적림상자료진행분석，근거치료방법적불동분위연합조화대조조，비교량조재치료8주시간후적내경복사효과、최종림상료효화불량반응정황。결과：치료8주후내경복사연합조총유효솔위90．48％，대조조위80．95％；림상치료효과연합조총유효솔92．86％，대조조위30．95％；불량반응연합조발생5례，대조조발생23례；량조내경복사효과、림상효과화불량반응발생정황대비차이균무통계학의의（ P＞0．05）。결론：미사랍진연합익생균치료염증성장병구유흔호적효과，치득림상추엄응용。treatment and compared the two groups after 8 weeks of treatment effect of endoscopy review ， the final clini-cal efficacy and adverse reactions ．Result：After 8 weeks ， the total effective rate of combination group and was 90．48％and 80．95％and respectively；The total effective rate of clinical outcomes in combination group and the control group was 92．86％and 30．95％；Adverse reactions occurred five cases of the combined group and 23 cases in control group；groups endoscopic review effects ， clinical efficacy and adverse events were not significantly different compared between two groups ．Conclusion： Mesalazine combined probiotics for the treatment of inflammatory bowel disease has a good effect ， worthy of clinical application ．
Objective:To investigate the efficacy of mesalazine combined probiotics inflammatory bowel disease .Method: Take retrospective analysis method to analyze clinical data of 42 IBD using mesalazine treatment and 42 with mesalazine combined probiotics method which randomly selected from March 2010 to September 2012.Divided into control groups and combination group according to the different methods of treatment and compared the two groups after 8 weeks of treatment effect of endoscopy review , the final clinicalefficacy and adverse reactions.Result: After 8 weeks, the total effective rate of combination group andwas 90.48%and 80.95%and respectively; The total effective rate of clinical outcomes in combination groupand the control group was 92.86%and 30.95%; Adverse reactions occurred five cases of the combined groupand 23 cases in control group; groups endoscopic review effects, clinical efficacy and adverse events were notsignificantly different compared between two groups.Conclusion: Mesalazine combined probiotics for thetreatment of inflammatory bowel disease has a good effect, worthy of clinical application.
